optic neuritis semaglutide semaglutide and incident nonarteritic anterior ischemic optic neuropathy (NAION - SemaglutideNAION mechanism use of semaglutide is associated to an increased risk of NAION Navigating the Potential Link Between Semaglutide and Optic Nerve Concerns

NAIONsemaglutideReddit The growing popularity of semaglutide, a GLP-1 receptor agonist medication widely recognized for its efficacy in managing type 2 diabetes and promoting weight loss through brand names like Ozempic and Wegovy, has brought to light potential associations with certain neurological conditions. Specifically, emerging research and clinical observations are exploring a possible link between semaglutide use and an increased risk of non-arteritic anterior ischemic optic neuropathy (NAION). While this connection is still under active investigation, understanding the nuances is crucial for healthcare professionals and patients alike作者：L Wang·2025·被引用次数：21—This cohort study found that treatment withsemaglutideor tirzepatide was associated with increased risk ofopticnerve disorders, including ....

Understanding Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION)

Non-arteritic anterior ischemic optic neuropathy (NAION) is a serious, and often irreversible, condition characterized by sudden vision loss in one or both eyes.佛历2567年12月11日—Our study confirms thatuse of semaglutide is associated to an increased risk of NAION, but also that the excess absolute risk is low. It occurs due to a disruption of blood flow to the optic nerve head, which is a critical component of the visual pathway. Unlike its arteritic counterpart, NAION is not directly caused by inflammation of blood vessels作者：CC Chou·2025·被引用次数：86—Nonarteritic anterior ischemicoptic neuropathyoccurred in ≤10 cases, both in those usingsemaglutideand those not using GLP-1RAs after 1 year. Nonarteritic .... The exact etiology remains unclear, but it is generally understood to be triggered by a combination of local factors, such as the anatomy of the optic disc at risk, and systemic factors that can affect blood flow and vascular health. While optic neuropathy is a broad term, NAION is the specific condition drawing attention in the context of semaglutide作者：KY Chen·2025·被引用次数：5—Pharmacovigilance data and case reports have suggested a potential safety signal betweensemaglutide use and non-arteritic anterior ischemic optic neuropathy( ....

Emerging Evidence on Semaglutide and NAION

A growing body of research, including observational studies and case reports, has begun to investigate the potential association between semaglutide and an elevated risk of NAION.佛历2567年8月1日—Propensity-matched analysis in the T2D cohort indicated a higher risk of NAION for patients receivingsemaglutide(HR, 4.28; 95% CI, 1.62–11.29; ... Several prominent studies have highlighted this concern:

* A comprehensive matched cohort study involving 16,827 patients, as published by Hathaway and colleagues, indicated a higher risk of NAION in patients prescribed semaglutide compared to those on different non-GLP-1 RA medications.

* Another study suggested that semaglutide users are more than twice as likely to develop nonarteritic anterior ischemic optic neuropathy than individuals not taking the medication.

* Pharmacovigilance data and reports have also prompted the World Health Organization (WHO) to alert healthcare professionals and regulatory authorities about the risk of non-arteritic anterior ischemic optic neuropathy (NAION) in patients on semaglutideNewest Study of Semaglutide and NAION Finds No ....

It is important to note that while these studies point to an increased risk, the incidence of NAION in the context of semaglutide treatment is considered to be very rare. Some research confirms that the use of semaglutide is associated with an increased risk of NAION, but emphasizes that the excess absolute risk remains low.Semaglutide, type 2 diabetes, and the risk of nonarteritic ...

Mechanisms and Contributing Factors

The precise semaglutide NAION mechanism is not yet fully elucidated. However, researchers are exploring several avenuesBilateral Non-Arteritic Anterior Ischemic Optic Neuropathy .... One theory suggests that the rapid changes in blood glucose and blood pressure associated with the therapeutic effects of GLP-1 receptor agonists like semaglutide could play a roleNewest Study of Semaglutide and NAION Finds No .... Additionally, a study by Ahmadi and colleagues proposed that individuals with small Bruch's membrane opening diameters might be more susceptible to developing NAION during semaglutide treatment, suggesting a potential interplay between drug effects and pre-existing anatomical variations.

While the primary focus has been on NAION, the broader category of optic nerve disorders has also been examined.作者：EZ Karam·2025·被引用次数：13—Non-Arteritic Anterior Ischemic Optic Neuropathy (NA-AION)is generally triggered by local features such as optic disc at risk and systemic factors. Research by Wang and colleagues found that treatment with semaglutide or tirzepatide was associated with an elevated risk of optic nerve disorders, reinforcing the need for vigilance regarding the optic nerve's health in patients using these medications.Semaglutide may be associated with non-arteritic ischemic ...

Distinguishing from Optic Neuritis

It's important to differentiate NAION from optic neuritis, another condition affecting the optic nerve.risk of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) Optic neuritis is characterized by inflammation of the optic nerve and often presents with symptoms like eye pain and temporary vision loss. While one study noted that the highest rate of optic neuritis historically belongs to the 45-54 age group, and indicated the condition appears to be increasing in that demographic, the current concern surrounding semaglutide specifically centers on the ischemic nature of NAION, not inflammatory optic neuritis. However, the mention of optic neuritis in some search results highlights the broad spectrum of visual disturbances that patients and clinicians inquire about.

Clinical Implications and Recommendations

The implications of these findings necessitate a proactive approach from healthcare providers. The understanding that semaglutide can nudge opticians and ophthalmologists suggests a heightened awareness in the medical community. Clinicians prescribing semaglutide should be aware of the potential, albeit rare, risk of NAION. Patients should be encouraged to report any sudden changes in vision, such as blurred vision, loss of peripheral vision, or visual distortions, immediately.

* Monitoring: Regular eye examinations, particularly for individuals with pre-existing risk factors for vascular or optic nerve conditions, may be advisable.

* Patient Education: Open communication about potential side effects, including the rare risk of vision changes, is crucial. Patients should be empowered to discuss any visual concerns with their doctors.

* Further Research: Continued research is vital to confirm the association, understand the underlying mechanisms, and identify individuals who may be at higher risk. Studies investigating the effect of semaglutide and GLP-1 RAs on risk of non-arteritic anterior ischemic optic neuropathy are ongoing and will be critical in refining clinical guidance.

Conclusion

In conclusion, while semaglutide offers significant therapeutic benefits for many patients, the potential association with non-arteritic anterior ischemic optic neuropathy (NAION) warrants careful consideration. The current evidence suggests a rare but increased risk. Healthcare professionals play a key role in educating patients, monitoring for potential symptoms, and contributing to ongoing research effortsA new study is the first to discover that people prescribedsemaglutide, sold as Ozempic and Wegovy, have a higher risk of developing a form of blindness.. This collective vigilance will help ensure that the benefits of semaglutide can be maximized while mitigating any potential risks to visual health作者：CX Cai·2025·被引用次数：86—Semaglutide, a glucagonlike peptide-1 receptor agonist (GLP-1RA),has recently been implicated in cases of nonarteritic anterior ischemic optic.... The discussion around Semaglutide and its potential link to NAION is an evolving area, emphasizing the importance of staying informed about the latest medical findings.Nonarteritic Anterior Ischemic Optic Neuropathy and ...